You are here

Article Text

Article menu
Download PDFPDF
Letter
Longlasting effects of immunoadsorption in severe Sjögren’s syndrome
  1. M Böhm1,
  2. T Dörner2,
  3. F Knebel1,
  4. A Bruns2,
  5. N Jochmann1,
  6. G Baumann1
  1. 1Department of Medicine, Cardiology, Angiology and Pneumology, Charité University Medical Centre, Berlin, Germany
  2. 2Department of Medicine, Rheumatology and Clinical Immunology, Charité University Medical Centre, Berlin, Germany
  1. Correspondence to:
    Dr M Böhm
    Department of Medicine, Cardiology, Angiology, and Pneumology, University Hospital Charité, Schumannstr 20/21, D-10098 Berlin, Germany; marko.boehmcharite.de

https://doi.org/10.1136/ard.2003.011486

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Despite advances in understanding the immunopathogenesis of Sjögren’s syndrome, successful therapeutic interventions are extremely limited.

    CASE REPORT

    With this in mind we began a immunoadsorption treatment of a 38 year old woman, diagnosed 1.5 years ago with Sjögren’s syndrome. She reported dry eyes and mouth for several months and intermittent arthralgias, especially of the small finger joints and elbows, as well as swollen joints of the hands, elbows, and ankles for six years. During the six months before treatment her joint symptoms had increased significantly and considerably impaired everyday activities. A Schirmer’s test was positive. The antinuclear antibodies and rheumatoid factor were raised, autoantibodies against Ro/SSA and La/SSB were positive. Thus, the patient fulfilled four of six revised criteria of primary Sjögren’s syndrome.1

    Previous corticoid treatment (prednisolone 20 mg …

    View Full Text